National Cancer Institute Fills Three Top Positions
Andrew C. von Eschenbach, M.D., director of the National Cancer
Institute (NCI), recently announced the appointments of two new
deputy directors within his office and the appointment of the director
of the Division of Cancer Treatment and Diagnosis (DCTD), a position
without a permanent leader since 2001.
Karen H. Antman, M.D., who will officially assume her position
on April 18, 2004, will offer strategic scientific direction as
deputy director for Translational and Clinical Science. Mark S.
Clanton, M.D., M.P.H., the deputy director for Cancer Care Delivery
Systems, is providing strategic leadership in health care system
design. James H. Doroshow, M.D., F.A.C.P., in addition to his role
as director of DCTD, is leading the NCI Clinical Trials Working
"We are fortunate to have these new leaders and visionaries
at NCI," said von Eschenbach. He recently reorganized his office
to establish four deputy director positions to help organize and
orchestrate the entire NCI portfolio across "the realm of the
discovery, development, and delivery continuum."
In her new role, Antman will direct a national, cross-cutting
research program that includes the NCI-designated Cancer Centers
Program, the disease-oriented Specialized Programs of Research Excellence,
and other translational programs aimed toward meeting the 2015 goal
of eliminating suffering and death due to cancer. Antman was previously
director of the Columbia University Comprehensive Cancer Center
and chief of the University's Division of Medical Oncology. She
recently co-chaired the Sarcoma Progress Review Group, which made
recommendations to NCI for advancing diagnosis and treatment of
Clanton, former president-elect of the American Cancer Society,
brings expertise in managed care, health plan administration, and
public health to his role of expanding, increasing, and enhancing
the NCI research portfolio to improve evidence-based cancer care
delivery. Clanton will coordinate health economics, clinical effectiveness,
and cancer patient outcomes research to maximize NCI's ability to
influence the delivery of care to people with cancer, particularly
those most affected by health disparities. Previously, Clanton served
as chief medical officer of Blue Cross and Blue Shield of Texas.
Doroshow newly arrived from his 20-year position at the City of
Hope in Los Angeles, where he served both as chairman of the Department
of Medical Oncology and Therapeutics Research and as associate director
for clinical research at the City of Hope Comprehensive Cancer Center-is
recognized internationally for productivity and leadership in the
field of cancer therapy. Under his direction, the NCI Clinical Trials
Working Group will develop new paradigms to re-direct the clinical
trials infrastructure from the traditional single agent safety,
efficacy, comparison process to one of multiple interventions using
innovative study designs, end-point determinations, enhanced public-private
partnerships, and a shared bioinformatics platform.
Anna Barker, Ph.D., formerly NCI deputy director for Strategic
Scientific Initiatives, assumed her new role as deputy director
for Advanced Technologies and Strategic Partnerships in February.
The deputy director position for Integrative Biology and Molecular
Oncology is still in the process of being filled.
For more information about cancer, visit the NCI Web site at http://www.cancer.gov
or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).